Abstract:
This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.
Abstract:
Anti-cadherin and anti-ZO-1 agents and compositions, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti- scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.
Abstract:
Methods, compounds, compositions, kits and articles of manufacture comprising anti- connexin polynucleotides for prevention and/or treatment of abnormal scars, including keloid scars, hypertrophic scars, atrophic scars, and widespread scars.
Abstract:
Methods, compounds, compositions, kits and articles of manufacture comprising anti- connexin polynucleotides for prevention and/or treatment of abnormal scars, including keloid scars, hypertrophic scars, atrophic scars, and widespread scars.
Abstract:
Compositions, articles, devices and methods for the treatment of fibrosis and fibrotic diseases, disorders, and conditions in humans and non-human animals.
Abstract:
Methods, compounds, compositions, kits and articles of manufacture comprising anti- connexin agents for treatment of orthopedic disorder, disease, or condition, and promoting post-surgical wound-healing.
Abstract:
Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.